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Introduction
This publication is the first in a series dedicated to prevalent illicit synthetic stimulant drugs, also 
known as amphetamine-type stimulants (ATS). The ATS category is made up of two groups of 
substances:
•  the ‘amphetamines’, which includes amphetamine, methamphetamine and related substances 
such as fenetylline, methylphenidate, phenmetrazine, cathinone, etc.; 
• the ‘ecstasy-type’ drugs (MDMA and its close relatives MDA and MDEA). 
This study focuses on the supply and use of methamphetamine in Europe, set in a global context. 
Amphetamine and ecstasy will be addressed in future publications in the series. 
Methamphetamine is probably the most widely consumed synthetic stimulant in the world. In many 
countries across the globe it is reportedly the second most prevalent illicit drug after cannabis. Its 
prevalence is a result of both historical and recent factors. From its initial synthesis from ephedrine 
in 1919, methamphetamine use has evolved over the years. Originally it was a legal, experimental 
substance used as a medicine; it was then used as a stimulant and performance-enhancer by 
fighters in World War II; in the late 1940s it was a licit product of mass consumption and a widely 
prescribed medication; and since the 1970s it has been an illicitly used and produced drug that 
has gained dramatically in popularity in some parts of the world since the 1990s.
Globally today, methamphetamine is associated with significant public health, social and security 
problems. These are especially visible in North America and Asia. Moreover, the use of the drug is 
also spreading to new areas, notably in the southern hemisphere and to some developing and 
transitional countries. 
Although methamphetamine use remains limited in Europe as a whole, especially in comparison to 
other stimulants like cocaine and amphetamine, it is the cause of significant harm in some Member 
States. In the Czech Republic it is the most used illicit drug after cannabis. Since the late 1990s, 
methamphetamine problems have also grown in the Slovak Republic and the drug is now 
responsible for an important component of the country’s drug problem. Some limited diffusion may 
also be occurring in other countries in Central and Eastern Europe. Moreover, large seizures in 
recent years in the Nordic and neighbouring countries suggest that methamphetamine is 
increasingly available in these countries and may to some extent be replacing amphetamine in the 
stimulant market. This, combined with the relative ease with which the drug can be produced, and 
some evidence of growing methamphetamine production outside the areas in which it has 
traditionally been found, raises concerns that future supply-driven diffusion cannot be ruled out. 
Thus, monitoring developments in the use or supply of this drug remains an important concern for 
both Europol and the EMCDDA. 
When considering the potential implications of any diffusion of methamphetamine use across 
Europe, it is important to note that users may find the effects of amphetamine and 
methamphetamine practically indistinguishable. This fact may facilitate the spread of 
methamphetamine in markets where amphetamine is currently the stimulant of choice, such as 
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Methamphetamine
Methamphetamine is a synthetic substance that acts as a stimulant of the central nervous system, and is 
closely related to amphetamine. Methamphetamine base is a colourless volatile oil, insoluble in water. The 
most common salt is hydrochloride, which occurs as a white or off-white powder or as crystals soluble in 
water. Illicit products mostly consist of powders, but the pure crystalline hydrochloride, sometimes referred to 
as ‘ice’, may also be found. 
‘Street’ terms for methamphetamine include speed, crank, meth, crystal meth, ice, Pervitin, yaba and shabu 
(some countries in the Far East, especially Thailand, the Philippines and Japan).
Methamphetamine may be ingested, snorted and, less commonly, injected or smoked. Unlike the sulfate salt 
of amphetamine, methamphetamine hydrochloride, particularly the crystalline form, is sufficiently volatile to 
be smoked. When smoked, it reaches the brain much more rapidly and this mode of use is particularly 
associated with a high risk of producing dependence and health problems. Injection of methamphetamine 
carries with it not only a high risk of developing dependence and experiencing health problems but also the 
same viral infection hazards (e.g. HIV and hepatitis) as are found with the injection of other drugs. 
Although methamphetamine is a more potent CNS-stimulant than amphetamine, in uncontrolled situations the 
effects are usually difficult to distinguish. It is important to note here that there is a large variation in reported 
purities of these stimulants across Europe, and other factors such as the acidity of an individual’s urine which 
will effect the rate the drug is metabolised in the body. Methamphetamine increases the activity of the 
noradrenergic and dopamine neurotransmitter systems. The S -isomer has greater activity than the R-isomer. 
Fatalities directly attributed to methamphetamine are rare, but acute intoxication causes serious 
cardiovascular disturbances as well as behavioural problems, including paranoia and violence. Chronic use 
of methamphetamine causes neurochemical and neuroanatomical changes. The symptoms of dependence 
include paranoid, tactile and other hallucinations. These effects may outlast drug use, although they usually 
resolve eventually. 
Although it has occasional therapeutic uses, most of the methamphetamine available globally is 
manufactured illicitly. Methamphetamine is under international control. The S -enantiomer is listed in Schedule 
II of the United Nations 1971 Convention on Psychotropic Substances. The racemate (a 50:50 mixture of the 
R- and S -stereoisomers) is also listed in the same Schedule, but the R-enantiomer is not separately identified 
in the Convention.
Source: EMCDDA (2007–08), Drug profiles, European Monitoring Centre for Drugs and Drug Addiction, 
Lisbon (http://www.emcdda.europa.eu/publications/drug-profiles); Europol.
Finland, Norway and Sweden. Outside of Europe, the smoking of methamphetamine and 
crystalline methamphetamine in particular, is a behaviour highly associated with negative public 
health implications. This underscores the need for careful monitoring of the availability, 
characteristics, and modes of use of different stimulant drugs across Europe and is one reason why 
the EMCDDA and Europol have selected methamphetamine as the first synthetic stimulant to be 
covered in their series of joint publications.
This report provides a condensed review of key issues relevant to understanding how Europe stands 
vis-à-vis the global methamphetamine problem today. At various points in the document, 
background information on the chemistry of methamphetamine, production methods and their 
specificities, as well as key European figures are provided. 
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Analysis begins with a summary of the history of methamphetamine in Europe, set in a global 
context. There then follows an outline of the situation regarding current methamphetamine trends 
worldwide, and recent changes in the international trafficking patterns of indispensable precursor 
chemicals. 
The publication then focuses on Europe. The latest trends in the use, manufacture and trafficking of 
methamphetamine within Europe are examined, and the role of Europe in the international trade of 
precursors is described. Finally, the report provides an overview of initiatives at the international 
and European Union levels to address methamphetamine production and precursor trafficking and 
their consequences.
Methamphetamine in Europe at a glance
•  Among European countries, the highest prevalence of methamphetamine is in the Czech Republic and the 
Slovak Republic, although many other countries sporadically report its availability, use or seizure.
•  Available national estimates of problem methamphetamine use: between 2.8 to 2.9 cases per 1 000 
people aged 15–64 years in the Czech Republic; between 1.5 to 4 cases per 1 000 people aged 15–64 
years in the Slovak Republic.
•  Almost 4 500 seizures were reported by 17 countries in 2007, resulting in the interception of about 340 
kilograms of methamphetamine. 
•  Countries reporting the largest number of seizures (in descending order): Norway, Germany, Slovak 
Republic, Sweden and Latvia.
•  Countries reporting the largest quantities seized (in descending order): Norway, Sweden, Lithuania, 
Finland and Latvia.
•  Typical (modal) price of methamphetamine: from EUR 8.5 to EUR 36.5 per gram. 
•  Typical (modal) purity of methamphetamine varies considerably: from 3 % to 79 %.
•  Common adulterants or cutting agents include caffeine, glucose and other sugars and, less commonly, 
ephedrine or ketamine. Methamphetamine has also been found as an adulterant in ecstasy tablets.
Source: EMCDDA, 2009 and 2007–08 (2007 data unless otherwise indicated).
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Methamphetamine: The global context
Historical background
Methamphetamine was first synthesized from ephedrine in Japan in 1919 by Akira Ogata. 
Ephedrine had been isolated from the Ephedra vulgaris (1) plant by another Japanese chemist, 
Nagayoshi Nagai, some years earlier (Zábranský, 2007; Ogata, 1919). The drug was patented in 
1920, then marketed in hydrochloride form by the Burroughs Wellcome company under the brand 
name ‘Methedrine’ (Logan, 2002). 
In the 1920s and 1930s, the medical and paramedical 
use of methamphetamine and amphetamine 
(Benzedrine, Dexedrine) increased in Europe and in the 
West in general. For instance, amphetamine was 
prescribed for depression and other mood disorders in 
the United Kingdom, but was also sought out for its 
stimulant effects (by students, for instance). Problematic 
side effects of chronic and non-medical use of 
amphetamine, including hypertension, depression, 
dependence, and psychiatric disturbances have been 
documented since the late 1930s (ACMD, 2005). 
Nevertheless, both amphetamine and methamphetamine 
enjoyed widespread acceptance as safe and beneficial 
drugs among the medical profession and the public at 
large, well into the 1960s. 
In 1938, the Berlin-based Temmler pharmaceutical 
company started production of methamphetamine under 
the brand name ‘Pervitin’ (Griffiths et al., 2008). During 
World War II, Pervitin was widely distributed to 
German troops to enhance performance and increase 
concentration, and became known in Germany as ‘Pilot’s chocolate’, and ‘Pilot’s salt’. The drug also 
gained popularity among German civilians (UNODC, 2003; Zábranský, 2007). 
In Japan, methamphetamine was first manufactured in 1941. It was supplied to Japanese soldiers, 
especially pilots, and to workers in key war industries under the brand name ‘Philopon’ from 1942 
onwards. Methamphetamine use spread in the Japanese population, who dubbed the drug ‘shabu’ 
(Tamura, 1989). The name is still used today for illicit methamphetamine tablets in parts of south-
east Asia. In the Allied camp, although millions of methamphetamine tablets were supplied to US 
military personnel (AMCD, 2005), the stimulant given to soldiers was more commonly 
(1)  Chinese herbalists have used ‘Ma Huang’ (Ephedra vulgaris) from the first century AD, in particular to treat 
asthmatic conditions (AMCD, 2005).
Figure 1.  Ephedra vulgaris
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amphetamine, which again also resulted in some subsequent post-war diffusion of use to civilian 
populations (Zábranský, 2007) (2). 
Fuelled by the sale of the enormous war surplus of (meth)amphetamine to the general population, 
this initial wave of synthetic stimulant use continued into the late 1940s. There was widespread 
medical and non-medical use of amphetamine in Europe (especially in Sweden and the United 
Kingdom), amphetamine and methamphetamine in North America (notably in the United States), 
and methamphetamine in the Far East (specifically Japan) (Zábranský, 2007; AMCD, 2005; 
UNODC, 2003; Case, 2005; Tamura, 1989). 
Although initial restrictions on the prescription and sale of amphetamine and methamphetamine 
products (tablets, ampoules, inhalers) were imposed in all three regions in the early 1950s, demand 
remained high, and (meth)amphetamine use continued in the 1950s and 1960s (AMCD, 2005; 
Tamura, 1989), especially among women (Case, 2005) (3). 
The overwhelming majority of the (meth)amphetamine available at that time was manufactured 
legally by pharmaceutical companies and prescribed by medical practitioners for a wide variety of 
disorders, including depression, attention deficit disorder, alcoholism, obesity and anorexia 
(AMCD, 2005; Case, 2005; NDLERF, 2005). However, during the 1950s in Japan and 1960s in 
North America and Europe, supply channels began to shift and illicit sources of supply gradually 
emerged, probably responding to the increasing restrictions placed on the medical use of these 
drugs (Tamura, 1989; Case, 2005; AMCD, 2005a). 
These supply channels reportedly took three forms — illegal distribution or diversion of domestically 
manufactured pharmaceutical products; illegal importation of products manufactured abroad; and 
illicit domestic manufacture (Tamura, 1989; AMCD, 2005; Case, 2005; ODCCP, 2001) (4). In some 
instances, pharmaceutical firms supplied such channels (Tamura, 1989), while in other cases 
criminal organisations became involved, such as Japanese gangsters in the 1950s and US biker 
gangs in the 1960s (Tamura, 1989; Case, 2005). 
In Europe, the United Kingdom experienced increasing misuse of ATS. From the 1950s, 
amphetamine obtained from licit medical prescription was diverted into the illicit market. By the 
1960s, this trend reached epidemic proportions in some cities (ACMD, 2005). From 1968, 
prescribed methamphetamine contained in ‘Methedrine’ brand capsules that were legally used in 
the treatment of cocaine addicts, began to be diverted into the illegal market, causing a localised 
epidemic of intravenous methamphetamine use. Over time, methamphetamine and amphetamine 
diverted from therapeutic use were replaced on the market by illicitly produced amphetamine 
(2)  An estimated 200 million amphetamine and methamphetamine tablets were distributed to US troops during 
World War II, while an estimated 72 million amphetamine tablets were supplied to British soldiers (AMCD, 
2005).
(3)  According to Case (2005), most of the 31 million (meth)amphetamine prescriptions written in the United States in 
1967 were issued to women.
(4)  The ODCCP (2001) notes that starting in the 1950s the illicit manufacture of methamphetamine was gradually 
displaced from Japan to Korea, the Philippines and later China, although methamphetamine was still 
manufactured legally in Japan at that time.
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sulfate and by the 1980s, methamphetamine had virtually disappeared from the UK’s illicit drugs 
market (ACMD, 2005) (5).
This pattern was common for most European countries where amphetamine, joined later by MDMA, 
have been the main ATS drugs used for a considerable period of time. A notable exception here is the 
Czech Republic where the illegal production and use of methamphetamine has been an important 
element in the country’s drug problem since the 1970s. At this time, a simple formula for 
methamphetamine production, known locally as Pervitin, was rediscovered, probably in Prague but then 
quickly spreading to the Czech, but not Slovak, parts of the country. Production was carried out usually 
by small groups of user-producers and was facilitated by the existence of the VUAB factory, which was 
an important manufacturer of ephedrine for the global licit market. Some of this output was diverted into 
the illicit market. Other pharmaceuticals that contain ephedrine or pseudo-ephedrine, such as ‘Solutan’ 
(later ‘Modafen’ and ‘Paralen plus’), were widely available and were used in the production of 
methamphetamine using the ‘reduction method’, together with other freely available chemicals.
Although the VUAB factory closed down its production in 2003 (Griffiths et al., 2008), illicit (but 
usually small-scale) methamphetamine production is still common in the Czech Republic.
Global methamphetamine production
The UNODC conservatively estimated in its World Drug Report 2008 that there were 14 million 
amphetamines users worldwide in 2006, approximately 55 % of whom would live in East and 
south-east Asia where the ATS most used is, overwhelmingly, methamphetamine (UNODC, 2008a) (6). 
The global production of ATS is estimated to have reached 494 tonnes in 2006, including 392 
tonnes of amphetamines, of which 266 tonnes was methamphetamine. Global methamphetamine 
production levels are reported to have fallen slightly in 2006 compared to 2005 (278 tonnes) and 
2004 (291 tonnes) (UNODC, 2008a) (7). 
Meanwhile, the number of ATS manufacturing facilities detected worldwide, including 
methamphetamine labs, has dropped markedly from 18 639 in 2004 to 8 245 in 2006. But this is 
attributed to a rapid decline in the detection of small-scale methamphetamine labs in the United 
States, which peaked in 2004 (UNODC, 2008b), and the UNODC warns that illicit 
methamphetamine production has not declined globally because it is ‘increasingly manufactured in 
super or mega-laboratories’ (UNODC, 2008a, p. 125) (8). 
(5)  Nonetheless, in recent years methamphetamine has become more prevalent in the United Kingdom, with reported 
incidents of production leading to methamphetamine being upgraded to a class ‘A’ drug.
(6) 2006 is the last year for which global statistics were available at the time of writing this report.
(7)  The UNODC reports that these are ‘point estimates’ of 2006 global outputs based on the following corrected 
ranges — ATS: between 421 to 574 tonnes; amphetamines: between 320 and 469 tonnes; no range given for 
methamphetamine (ranges not corrected for propagation of error are much wider) (UNODC, 2008a).
(8)  However, in 2009 methamphetamine manufacturing in small-scale labs from the pseudo-ephedrine contained in 
over-the-counter medicines seems to be making a come-back in some areas of the United States (Young, 2009).
(9)  However, this is not the case for BMK (P-2-P), a precursor frequently used to make amphetamine illicitly but which 
may be also used for methamphetamine, for which there are only limited licit applications in the European Union 
(mostly to manufacture medical amphetamine and methamphetamine) (Krawczyk et al., 2005). 
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Some specificities of methamphetamine production 
Globally, illicit methamphetamine is most frequently synthesized from the precursors ephedrine and 
pseudo-ephedrine. It may also be manufactured from 1-phenyl-2-propapone, also known as BMK (Benzyl 
Methyl Ketone) and P-2-P and phenylacetone, although BMK is more commonly used to manufacture 
amphetamine. Amphetamine and methamphetamine are rarely trafficked on intercontinental routes, unlike 
some of their precursors or plant-based illicit drugs like heroin and cocaine. Indeed, methamphetamine tends 
to be produced in or near the consumer markets, greatly lowering the risks associated with long-distance 
transportation and multiple border crossings. This is due to a combination of factors, outlined below. 
Methamphetamine (and ATS generally) production is not labour-intensive, it is easily hidden and protection 
requirements are much lower than in the case of plant-based drugs, which require work and attention over 
long growing cycles on large tracts of land that must be protected against thieves and law enforcement. 
Both ephedrine and pseudo-ephedrine are cheaply available worldwide, although enhanced control efforts in 
recent years seem to have made them somewhat harder to obtain. Because these precursors have widespread 
legal uses, especially by the pharmaceutical industry, very large amounts of them are traded worldwide every 
year, which complicates monitoring and detection efforts while making it easier to import them for illicit ends (9). 
This is also true for the other chemicals that are needed to produce methamphetamine (solvents, reagents, etc.), 
most of which have a wide variety of licit applications and are therefore difficult to monitor. 
In addition, a relatively small (and easily concealed) quantity of precursor is enough to manufacture sizeable 
— and valuable — amounts of methamphetamine. A kilogram of BMK may yield as much as 1.25 kg of 
methamphetamine (Krawczyk, 2005). In 2005, the mean price of a kilo of BMK was reported to be EUR 
900 on the black market in Europe (EUR 100 if bought legitimately) (Krawczyk et al., 2005), while the mean 
retail price of a gram of methamphetamine in, for instance, the Czech Republic, was reported at EUR 35 
(EMCDDA, 2007). If retailed entirely in one-gram doses of pure methamphetamine, a kilo of the drug could 
generate a gross earning in excess of EUR 43 750. This is a theoretical calculation since in the Czech 
Republic, methamphetamine production is usually conducted on a small scale and the mean purity at retail 
level was reported as 63 % in 2005 (EMCDDA, 2007), nonetheless, it does illustrate how profitable illicit 
methamphetamine manufacturing can be. 
The methamphetamine manufacturing process is flexible, since it is simple to synthesize the drug from a 
range of precursors and other chemicals through a variety of basic, often one-step, chemical processes.  
If one chemical is lacking, another can easily be used instead. The scale of production is also flexible, since 
the drug may be (and is) manufactured in facilities ranging from ‘kitchen labs’ using rudimentary know-how 
and technology and operated by the users themselves, to (increasingly) industrial premises equipped with the 
latest technology and run by organised criminal gangs (ODCCP, 2001; NDLERF, 2005; UNODC, 2008a). 
A final factor is that methamphetamine labs can be set up rapidly to supply a specific order and taken apart 
equally quickly to avoid detection. The equipment can easily be stored in a car, van or lorry and set up at 
another location.
Methamphetamine is predominantly illicitly produced near its main consumer markets in east and 
south-east Asia, North America, and Oceania (UNODC, 2008a). Nevertheless, in recent years 
methamphetamine production and use have spread to new regions, notably South Africa (UNODC, 
2008b, 2008c). Although these estimates should be treated with caution, they do suggest that 
methamphetamine is probably the most widely manufactured and used illicit synthetic stimulant in 
the world. 
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The methamphetamine precursors
Although the trade in methamphetamine rarely takes place across long distances (see box on  
page 11), the situation is quite different when it comes to its main precursors, ephedrine, pseudo-
ephedrine and, to a lesser extent, BMK. 
Commercial ephedrine and pseudo-ephedrine are currently produced by extraction from the 
ephedra plant, or by chemical synthesis. All three substances in bulk form are placed under 
international control and listed in Table I of the United Nations Convention against Illicit Traffic in 
Narcotic Drugs and Psychotropic Substances of 1988. However, the control regime applied to 
pharmaceutical preparations containing ephedrine and pseudo-ephedrine (e.g. cold remedies in 
tablet form) is not as strict (UNODC, 2008b). 
All three chemicals are produced and traded globally for legitimate ends. However, the global 
legitimate trade of BMK is more restricted compared with ephedrine and pseudo-ephedrine, 
reflecting the fact that BMK has few legitimate applications. In 2007, in data reported to the INCB 
by 18 UN Member States, world legitimate requirements of BMK amounted to a total of 164.5 
tonnes. In contrast, 80 countries reported legitimate requirements of bulk ephedrine totalling 827 
tonnes and 71 countries reported legitimate requirements of bulk pseudo-ephedrine totalling 1 315 
tonnes (INCB, 2009).
As far as illicit uses are concerned, it should be noted that, at world level since the 1980s, BMK has 
been gradually replaced by ephedrine and pseudo-ephedrine as the methamphetamine precursor 
of choice, and is now mainly associated with the illicit manufacture of amphetamine in Europe 
(UNODC, 2008b). However, some BMK is still used to synthesize methamphetamine in Europe 
(Europol, 2007e) and possibly elsewhere, since seizures or illicit manufacture of BMK outside 
Europe are reported to be increasing (UNODC, 2008b).
Although it is quite difficult to ascertain which countries are the main manufacturers of the three 
precursors, and therefore potential sources of raw material for illicit production, countries that 
manufacture BMK include China, India, Japan, the United States and the Russian Federation 
(Krawczyk et al., 2005). Furthermore, China, Germany and India are among the world’s largest 
manufacturers of ephedrine and pseudo-ephedrine; and China and India are the two countries most 
often reported as sources of seized illicit shipments of ephedrine and pseudo-ephedrine (UNODC, 
2008b; INCB, 2009). The illicit BMK found in Europe originates mostly from the Russian Federation. 
Illicit methamphetamine production is now reported to be better controlled by regulatory and law 
enforcement bodies due to the implementation of precursor control and prevention programmes. 
These have created more effective hindrances to the illegal diversion of precursors (at least for 
small-scale methamphetamine producers) (UNODC, 2008b), as has an increasing awareness of 
the risks inherent to ATS use (UNODC, 2008a). 
Nevertheless, in some regions such as North America producers have adapted by substituting 
controlled precursors with non-scheduled chemicals, such as N-acetylpseudoephedrine acetate, 
natural ephedra plant extracts and above all pharmaceutical preparations containing ephedrine 
and especially pseudo-ephedrine (UNODC, 2008b). 
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Similarly, trafficking routes have adapted in order to circumvent law enforcement and may shift 
further in future (Chouvy and Meissonnier, 2004; UNODC, 2008b). Recent reporting to the 
UNODC indicates illegal trafficking of more than 120 tonnes of ephedrine or pseudo-ephedrine 
through Africa and the Middle East (UNODC, 2008a). Seizures of large amounts of ephedra 
powder and plants, which are not placed under international control but whose trade is restricted 
in several countries, have been carried out in Europe in 2005–08 (UNODC, 2008b; INCB, 2009). 
Additionally, South and Central American countries reported increased attempted diversions of 
large amounts of pseudo-ephedrine during 2006–08. Recent illustrations include a significant 
seizure of 5 million pseudo-ephedrine tablets (reportedly shipped from Hong Kong) in Guatemala 
in 2008 (UNODC, 2008b), and the confiscation of a total of 1.2 tonnes of ephedrine in Argentina 
during the same year (INCB, 2009). In both cases, most of the seized precursors were probably 
intended for methamphetamine manufacturing in Mexico, although they could also have been for a 
methamphetamine lab that was found in Argentina in July 2008 (INCB, 2009; UNODC, 2008a). 
The shift in the international trafficking routes for methamphetamine precursors also has 
consequences for Europe. These are reviewed in the next section.
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Methamphetamine issues in the European 
context
Europe is a producer of methamphetamine and of two of its three main precursors. It is also a 
consumer of the drug and a transit territory for international shipments of precursors from Asia 
destined for North America, especially Mexico. However, the social and health problems posed by 
the drug are not found on the same scale as those in North America and Asia. Two factors are 
important here. First, significant methamphetamine use remains limited in Europe to a few countries 
in central Europe, although methamphetamine may now be replacing amphetamine on the illicit 
market in some Nordic and Baltic countries. Second, the health impact of methamphetamine use is 
likely to be influenced by the route of administration adopted. The smoking of the drug, especially 
in its crystalline form, is likely to be particularly worrying from a public health perspective. 
However, in contrast to other parts of the world, this form of use of the drug is not currently common 
among European consumers.
Caution is required in any assessment of methamphetamine trends since sensitive data on emerging 
drug use patterns are difficult to collect and analysis is complicated, especially when demand-side 
and supply-side data do not substantiate each other. However, even if the current use of 
methamphetamine remains very limited in most of Europe, sufficient information does exist to 
suggest that we cannot be complacent about the possibility of the future spread of this drug. 
Although overall the indicators in place do not show an increase in methamphetamine use, some 
supply-side data suggest that methamphetamine is gradually becoming more available. 
In some countries in Eastern Europe, prevalence data also suggest that the use of the substance 
might be spreading. In the Slovak Republic methamphetamine use and problems have increased 
dramatically since 2002 and now the drug is responsible for a significant proportion of treatment 
demands. Some data also point to increased availability in Hungary, Poland and Germany, 
although overall levels of use still appear relatively low. In the Czech Republic, some evidence 
exists to suggest that methamphetamine use may also be diffusing from the stable chronic 
population into the recreational drug scene. This would be a worrying development and point to 
potential for wider diffusion. Moreover, in some of the countries neighbouring the EU evidence is 
emerging that methamphetamine problems may also be growing, especially among young 
injectors. Recent studies among drug injectors in both the Ukraine and Georgia have found high 
levels of methamphetamine use and again this phenomenon seems to be a relatively recent 
development (Booth et al., 2008; Otiashvili et al., 2008).
Problem methamphetamine use
In contrast to other parts of the world, where the use of methamphetamine has increased in recent 
years, its use in Europe appears limited (Griffiths et al., 2008). Since the early 1970s, its use in 
Europe has been concentrated in the Czech Republic and, more recently, the Slovak Republic. 
These are the only two European countries to report recent estimates of problem use of ‘Pervitin’, as 
methamphetamine is known there. In 2007, in the Czech Republic there were estimated to be 
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approximately 20 400–21 400 problem users (2.8 to 2.9 per 1 000 aged 15–64 years), twice the 
estimated number of problem opioid users; and in the Slovak Republic there were approximately 
5 800–15 700 problem users (1.5 to 4.0 cases per 1 000 aged 15–64 years), around 20 % fewer 
than the estimated number of problem opioid users (EMCDDA, 2009).
In the last five years, the reported demand for treatment related to methamphetamine use has been 
increasing in both the Czech Republic and the Slovak Republic. Methamphetamine became the 
primary drug most often reported by those requesting treatment for the first time in the Slovak 
Republic in 2006, and in 2007 it accounted for 26 % of all drug treatment requests. Use of the 
drug was not significantly reported in treatment populations before 2000 and methamphetamine 
problems in the Slovak Republic can be considered a relatively recent development. In the Czech 
Republic, 61 % of all drug treatment clients report methamphetamine as their primary drug 
(EMCDDA, 2009) and the drug accounts for around two thirds of estimated problem drug users. 
Clients in treatment for methamphetamine often report high rates of injecting drug use: 41 % in the 
Slovak Republic and 82 % in the Czech Republic. 
Data on the situation prevailing in the Nordic and Baltic countries are difficult to interpret, 
especially because users (especially those who inject the drug) may find it difficult to differentiate 
between methamphetamine and amphetamine, but a number of reports suggest that more 
methamphetamine is available at retail level now than was previously the case. Overall, data on 
drug consumption in this area remains weak, making trends difficult to interpret. However, some 
data does point to increased use of the drug. For instance, in Norway, methamphetamine was 
reported to be a factor in some 10 % of traffic accidents in 2003, while in 2006 it was 20%. 
Seizures in Nordic countries suggest that methamphetamine may be replacing amphetamine, to 
some extent, in these markets. This may be a supply-driven change reflecting dynamics in illicit 
drug production. Many Nordic countries have a long-standing problem with the injecting of 
amphetamines and the public health implications of any possible substitution of methamphetamine 
for amphetamine among these populations remain unclear. 
As noted already, apart from the Czech and Slovak Republics and possible recent changes in 
Nordic and Baltic countries, levels of methamphetamine use still remain low overall in Europe. That 
said, some diffusion in use does now appear to be taking place in some central European countries 
and some neighbouring countries to the EU report a growing problem with the drug. In western 
and southern Europe, however, countries report only very limited use of methamphetamine mostly 
restricted to experimentation in some high-risk populations. The available data do not suggest that 
the popularity of methamphetamine is increasing or that it is spreading to new populations of users 
in these countries. It is not clear what factors have impeded the spread of methamphetamine use in 
many parts of Europe but some studies have reported consumer and market resistance to the drug. 
It is also possible that a growing cocaine market in many western European countries has limited 
the potential opportunities for the spread of other stimulants. This conclusion remains speculative, 
but does point to a pressing need to understand better both the consumer and market factors which 
may inhibit or encourage the future spread of methamphetamine use in Europe.
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Methamphetamine production
Methamphetamine is most commonly produced by the reduction of ephedrine or pseudo-ephedrine, 
together with the use of other chemicals. Most of these chemicals are readily available household 
products. In this regard, it is important to note that, following the recent imposition of restrictions on 
the trade in bulk ephedrine and pseudo-ephedrine, there is a growing trend for illicit 
methamphetamine manufacturers to obtain these precursors by extraction from some pseudo-
ephedrine-based tablets sold as over-the-counter cold remedies. This is especially the case in the 
Czech Republic (10). This trend makes it more difficult for the authorities of the countries concerned 
to control methamphetamine production effectively.
Figure 2.  Seized packages of over-the-counter cold remedies containing  
pseudo-ephedrine used to manufacture methamphetamine in the Czech 
Republic (2007)
The synthesis of the precursors with other chemicals into the end-product methamphetamine is 
relatively simple. However, most methods involve flammable and corrosive chemicals and may 
therefore cause serious injuries and even death, while producing varying amounts of toxic waste 
that are often disposed of unsafely and may cause environmental damage (see box on page 17). 
(10)  However, a decision by the State Institute for Drug Control of the Czech Republic in May 2009 imposed 
restrictions on the sale of pseudo-ephedrine containing OTC products. These include prohibiting mail order sales, 
setting a maximum dose sold per patient per month (1 800 mg of pseudo-ephedrine), and registering sales in a 
‘central repository of electronic prescriptions’ also containing data on patients.
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Health and environmental risks posed by illicit methamphetamine production
In all methamphetamine production methods the following three groups of chemicals are present, which may 
be toxic: solvents; metals and salts; and acids and bases. Contamination by inhalation and skin exposure are 
the most likely hazards.
Inhaling solvents at low levels of concentration can cause eye, nose and throat irritation, whilst high-
concentration inhalation can result in intoxication, loss of consciousness, and liver and kidney impairments.
As most metals and salts are stable solids, the risk of injury by mere exposure is minimal. However if they are 
present in the air as dust, vapour or fumes they can be extremely corrosive in the presence of moisture. This 
is especially the case for sodium, potassium or sodium hydroxide. Aluminium hydride presents a risk of fire 
and explosion.
Acids or bases may be present as volatile gases or liquids, creating a risk for inhalation resulting in eye irritation, 
inflammation and corneal injury. Inhalation can also cause mucous membrane irritation, chest pain and 
shortness of breath, and in severe cases bleeding in the lungs. Direct contact can cause severe eye or skin burns.
Where the illicit production of methamphetamine takes place, contamination of the production location is 
inevitable. 
Methamphetamine production is often carried out through one-step reaction methods, resulting in less 
chemical waste than amphetamine, which involves several steps. Although no data is available on the 
amount of waste occurring as a result of methamphetamine production in Europe, US federal authorities 
estimate that the production of 1 kg of methamphetamine results in a total of 3 kg of waste, depending on 
the skills of the producer. Such waste consists mainly of chemicals, including ether, Freon, acetone, 
anhydrous ammonia, toluene, sodium hydroxide, sulphuric acid, lithium and red phosphorus (DEA, n.d.). All 
are toxic and should be disposed of following specific procedures in order to preserve the environment. 
However, such waste is often dumped in the environment or drained into the sewer, causing environmental 
pollution. Cleaning up methamphetamine labs or dump sites is a costly and hazardous task (Oregon 
Department of Health and Human Services, 2005). 
There are five known methamphetamine production methods in Europe. The three most common are 
lithium-ammonia, hypophosphorous acid/iodine and hydriodic acid/red phosphorus. All three are 
simple, one-step reactions of ephedrine or pseudo-ephedrine carried out using glass or stainless steel 
equipment. In addition to the precursor (pseudo-)ephedrine, the following chemicals are employed: 
•   Lithium/ammonia: lithium or sodium metal, ammonia, solvents and hydrochloric acid are needed. 
There is a danger that hydrogen gas and toxic fumes will be created. 
•   Hypophosphorous acid/iodine: iodine, hypophosphorous acid, solvents and hydrochloric acid 
are added. 
•   Hydriodic acid/red phosphorus: red phosphorus, hydriodic acid, solvents and hydrochloric acid 
are added. If overheating occurs phosphine will be created, and burning red phosphorus makes 
it turn into white phosphorus. This method involves corrosive and flammable hazards (Europol, 
2007b, 2007c, 2007d). 
The hypophosphorous acid/iodine and hydriodic acid/red phosphorus methods are most frequently 
used for the illicit manufacture of ‘Pervitin’ in the Czech Republic. 
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The two remaining methods, the Leuckart method and the reductive amination method, synthesize 
methamphetamine from BMK and are less frequently used (Europol, 2007d).
All of these methamphetamine production methods strongly depend on the availability of the 
precursors and the know-how of the producers. It should be noted that whilst the ‘red phosphorus’ 
production methods using ephedrine or pseudo-ephedrine are mainly found in the Czech Republic, 
Slovak Republic, Germany and the Netherlands, methamphetamine seized from Lithuanian 
organised criminal groups is produced with BMK as the precursor.
In 2006–08 Europe reported to the UNODC the largest increase in detection of 
methamphetamine-related production sites outside North America, although in 2006 Europe only 
accounted for an estimated 0.8 % of the quantity of methamphetamine seized in the world 
(UNODC, 2007). These production sites were mainly located in central and eastern Europe, 
overwhelmingly in the Czech Republic, and in the Russian Federation (11). 
However, compared to production in east and south-east Asia, North America and Oceania, much of  
which is done in large manufacturing facilities, the production of methamphetamine in the Czech Republic 
is small-scale. Most of it appears to be carried out in so-called ‘kitchen labs’ (see Figure 3) operated by  
‘cooperatives’ or ‘squads’ of users for their own consumption (Zábranský, 2007), and they obtain the  
precursors, especially pseudo-ephedrine, from cold remedies sold without prescription in pharmacies (12). 
Figure 3.  Small-scale methamphetamine production facility set in a garage, Czech 
Republic (2007)
(11)  The Russian Federation reported the seizure of 137 methamphetamine sites (referred to as ‘Pervitin’ and 
‘Ephedron’ sites) in 2007; all were kitchen-type labs.
(12) E-mail from the National Drug Headquarters of the Czech Republic police, 18 March 2009.
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According to information received by Europol, in addition to the ‘kitchen labs’ reported by the 
Czech Republic, seven methamphetamine production sites were detected in Europe outside the 
Czech Republic in 2007, with one production site dismantled in Belgium, the Netherlands, Poland 
and Portugal, and three in Germany.
In 2008, Europol received 483 reports (13), and the majority of production sites (457) were 
so-called ‘kitchen labs’ reported by the Czech Republic. In addition to the small-scale facilities in 
the Czech Republic, 26 production sites (11 in Germany, one in Ireland, three in the Netherlands 
(mid-scale), one in Portugal, four in the Slovak Republic, three in the United Kingdom and three in 
Poland (14)) were also reported. In addition, Belgian police found a recipe for large-scale 
methamphetamine manufacturing when intervening on an amphetamine facility in 2008. 
Trafficking in methamphetamine and its precursors 
Intra-European trafficking
Europol has identified two main intra-European methamphetamine trafficking routes. On the first 
route, methamphetamine produced in the Czech Republic is exported by car to bordering 
countries, especially Germany (mainly Bavaria and Saxony) and the Slovak Republic (see Figure 4). 
The other route reportedly carries larger quantities of the drug. It links the Baltic States 
predominantly to Sweden and Norway. Analysis of seizure information from Norway and Sweden 
has identified a common modus operandi for trafficking significant amounts of methamphetamine of 
about 10 kg each time, although occasionally the smuggling may involve quantities of up to 50 kg. 
While both Scandinavian and Lithuanian criminal groups control methamphetamine trafficking to 
Nordic countries, Lithuanian nationals, using personal vehicles, mainly carry out the smuggling 
itself. Methamphetamine is usually concealed in custom-made hiding places or in other cavities of 
the cars and trafficked by regular ferry lines from Lithuanian, Latvian and/or Estonian ports via the 
Baltic Sea (see Figure 4).
Recent EMCDDA seizure data appear to corroborate the fact that the traffic in methamphetamine 
across the Baltic Sea involves larger amounts than the cross-border trafficking of Czech-
manufactured ‘Pervitin’ into neighbouring countries, since the quantities reported as seized in 2006 
and 2007 in the countries of the ‘Baltic Route’ (Finland, Latvia, Lithuania, Norway and Sweden) are 
several times larger than those reported by the Czech Republic and its neighbours (Austria, the 
Czech Republic, Germany, Hungary, Poland and the Slovak Republic) (see Figure 6). 
Outside these two main trafficking hotspots in northern and central Europe, recent developments 
suggest that some methamphetamine could also be produced in western Europe. For example, in 
(13) Statistical data for 2008 is provisional, as not all Member States have yet provided information to Europol.
(14)  One of the three methamphetamine production sites reported by Poland in 2008 used the red phosphorus 
production method, whilst the methods of production of the remainder are unknown.
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December 2007, Dutch authorities seized one tabletting unit together with 100 kg of MDMA powder, 
29 different logo punches and 8 kg of high purity methamphetamine. One of the punches 
represented a logo rarely found in Europe but frequently found on methamphetamine tablets 
manufactured in Asia. Another police operation in the Netherlands in February 2008 resulted in the 
seizure of a tabletting unit, MDMA, 2C-B and a small amount of methamphetamine (Europol, 2008b).
Figure 4.  Seized methamphetamine production facilities in 2008 and main 
trafficking flows
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Figure 5.  Trend in amounts of methamphetamine seized reported to the EMCDDA 
2001–06 and Europol 2007
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Figure 6.  Quantities of methamphetamine seized (kg) reported to the EMCDDA 
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Trafficking of precursors
Only around 6 % of global ephedrine seizures are made in Europe. However, a relatively new 
development has been the export, transhipment and diversion of ephedrine or pseudo-ephedrine. 
India is a major source, and consignments have been trafficked from/via various regions including 
the Balkans, Iran, the Philippines, Pakistan, Syria, the United Arab Emirates and Africa. 
The bulk shipments that cross through the European Union, mainly via Amsterdam, Brussels, 
Frankfurt am Main, London and Paris airports, are destined for Mexico. Some cases of exchange of 
ephedrine or pseudo-ephedrine for cocaine by criminal groups have been identified (Europol, 
2008a). In 2006–07 the Netherlands reported to Europol an attempted diversion amounting to 
more than 200 tonnes of ephedrine and pseudo-ephedrine, while German authorities seized 14.5 
tonnes of ephedrine and more than 1.6 million pseudo-ephedrine tablets in 2008. 
In addition, large amounts of ephedra extracts have been confiscated in Europe in recent years. For 
instance, 800 tonnes of diverted ephedra extracts were seized in Germany in 2005–06, while a 
seizure of 94 tonnes was performed in the Netherlands. In January 2007, Luxembourg reported the 
seizure of 2 tonnes of ephedra en route from Germany to Mexico (UNODC, 2008b). 
A shift in BMK trafficking in Europe seems to have taken place since the mid-2000s. Indeed, before 
law enforcement action against some precursor traffickers was taken in 2004, almost all of the 
BMK used illicitly in Europe came from China. At present, illicit BMK seems to be sourced mainly 
from the Russian Federation, although the UNODC noted a resurgence in BMK trafficking from 
China in 2007 (Europol, 2007e; UNODC, 2008b).
Up until 2006, there were limited indications that organised crime was involved in 
methamphetamine production and trafficking activities in the European Union. However, Nordic 
and Baltic countries recently reported to Europol that Lithuanian criminal groups were involved in 
methamphetamine trafficking. Combined with recent significant ephedrine and pseudo-ephedrine 
seizures, an increase in methamphetamine seizures in Europe, and the discovery of production sites 
in countries other than the Czech Republic, the Slovak Republic and neighbouring countries, 
including three mid-scale production sites in the Netherlands in the second half of 2008, this could 
indicate organised crime involvement in methamphetamine production and trafficking. This is a 
potential new threat for the European Union (Europol, 2008a) (15).
(15)  In May 2009, the Lithuanian authorities seized a mid-size methamphetamine production site in the Kaunas 
region, together with approximately 100 kg of high purity methamphetamine. The drugs were intended for the 
Norwegian market.
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European and international initiatives
The European Union, its Member States, and the international community have undertaken a range 
of initiatives to address methamphetamine production and trafficking. Three such initiatives are 
worth mentioning here. 
Europol and European Union Member States have developed Project Synergy, which is the main 
synthetic drugs project in the European Union. Project Synergy and its Analytical work file (AWF) 
gathers and exploits relevant information available within and outside of the Member States in 
order to discover links between different cases, identify new criminal targets and target groups, and 
initiate, support and coordinate the intelligence aspects of investigations, whilst enhancing 
information exchange, knowledge and experience in the area of synthetic drugs-related precursors 
and equipment (16).
The AWF has 21 participating Member States: Austria, Belgium, Cyprus, the Czech Republic, 
Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, the 
Netherlands, Poland, Portugal, Spain, Sweden and the United Kingdom. Eurojust became 
associated to the AWF in 2007, Australia, Canada and the United States in 2008, while Norway 
and Switzerland have been invited to become associated. 
Project Synergy also includes the Europol Illicit Laboratory Comparison System (EILCS) and the 
formerly Europol Ecstasy Logo System (EELS) now incorporated into a system covering all ATS, 
named the Europol Synthetic Drug System (ESDS), both incorporated within the general Europol 
Synthetic Drug Database System (ESDDS). The EILCS collates detailed photographic and technical 
information on synthetic drug production, storage and dump sites, enabling the identification of 
matches between seized equipment, materials and chemicals, initiating information exchange, 
backtracking investigations and forensic examination for the targeting of facilitators and criminal 
groups. 
The ESDS collates modus operandi, photographic and basic forensic information on significant 
seizures, enabling matches between seizures or seized punches to be identified, initiating 
information exchange, further investigations and forensic profiling for the targeting of criminal 
groups. Related criminal data arising from the findings of the ESDS and EILCS may be analysed 
within the AWF component. Furthermore, Europol specialists provide on-the-spot assistance to 
Member States in the dismantling of illicit synthetic drug production sites.
Project Synergy supports, and is supported by, the activities of the European Joint Unit on Precursors 
(EJUP), a multinational, multidisciplinary joint unit consisting of law enforcement national experts 
from Austria, Belgium, France, Germany, the Netherlands and the United Kingdom. The EJUP 
national experts are experienced in investigating serious criminal activity related to the diversions 
and trafficking of precursors. 
(16) AWF Synergy Data Collection Plan.
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Project Synergy also supports, and is supported by, European Union initiatives on the forensic 
profiling of synthetic drugs and related precursors for law enforcement purposes whereby 
significant seizures may be forensically matched, leading to or supporting ongoing intelligence 
analysis.
Mutual support also exists between the European Police Chiefs Task Force’s Cospol initiative and 
Project Synergy. The Cospol synthetic drug group comprises Belgium (Co-driver), Finland, France, 
Germany, Lithuania, the Netherlands (Driver), Poland, Spain, Sweden, the United Kingdom, Europol 
and Interpol.
The Global Synthetics Monitoring: Analyses, Reporting and Trends Programme (SMART) was 
launched by the UNODC in September 2008 in Bangkok, Thailand. It aims to assist UN Member 
States in generating, analysing and using synthetic drug information in order to design effective 
policies and interventions. The SMART Programme aims to provide information on the patterns of 
trafficking and use of synthetic drugs including methamphetamine by supporting targeted countries 
to better monitor trends, including detecting and reporting on new trends, while improving methods 
for exchanging comparable information.
Lastly, following Operation Crystal Flow (which ran from 1 January to 30 June 2007), the Project 
Prism Task Force coordinated by the International Narcotic Control Board (INCB) decided to 
continue exchange of intelligence on suspicious transactions and on backtracking investigations. 
The new initiative, called Operation Ice Block, took place from 2 January to 30 September 2008. 
Operation Ice Block focused on trade in ephedrine and pseudo-ephedrine, including 
pharmaceutical preparations and ephedra and, to the extent it is possible to identify such 
shipments, trade in P-2-P and phenylacetic acid involving countries in Africa, the Americas, west 
Asia and Oceania. As in previous activities, the primary tool for the identification of suspicious 
transactions was the PEN Online system. Operation Ice Block was supported by the governments of 
all major exporting and transit countries. During the nine-month active phase of the operations, the 
Board reviewed information on 2 057 shipments and identified 49 suspicious transactions, which 
led to the stoppage or seizure of shipments totalling 49 tonnes of ephedrine and pseudo-
ephedrine. 
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Conclusions
Overall, methamphetamine use in Europe remains limited and in most countries data do not point to 
increasing problems. In many countries, the most notable trend in stimulant drug use appears to be 
the continued growth in the popularity of cocaine. Methamphetamine remains by comparison a far 
more limited problem. However, trends in drug use and availability can change rapidly and a 
number of factors clearly point to the potential for methamphetamine problems to spread further.
The European market for stimulant drugs as a whole is large and these substances may to some 
extent replace one another — sometimes without users even being aware of the particular drugs 
they are consuming. Methamphetamine may have some advantages in this respect. It is simple to 
produce, and for small-scale production in particular the precursors can easily be obtained from 
pharmacies and household products. The traditional methods of production, still relevant to a large 
extent to the situation in the Czech Republic and the Slovak Republic, often involve small groups of 
users manufacturing the drug principally for their own needs. However, although this is still the 
model for the majority of producers, some methamphetamine production and trafficking operations 
seem to have become more professionalised, and forms of organised crime may even have 
become involved in recent years. Given the capacity of modern illicit production processes this 
could potentially increase the spread and availability of the drug on the European market.
Data from law enforcement in Europe, including discussions at the Cospol synthetic drugs group, 
point to a notable increase in the number of methamphetamine seizures and in the quantities of 
methamphetamine seized in Europe. There is a new movement and potential diversion of the main 
precursors via, from, and/or into, the European Union, which would seem to require a proactive 
targeted law enforcement response. Latest trends show increased production and tabletting, which 
might indicate that the size of production sites is increasing to mid-level. Regional developments 
both in central Europe (particularly the Czech Republic, Slovak Republic and south-eastern 
Germany) and trafficking trends in the Nordic and Baltic countries also indicate not only that the 
population of European countries moves around more and more, but also that drug preferences do 
as well. Europol (Europol, 2008a) and EMCDDA are closely monitoring this relatively new 
phenomenon.
The collection of reliable data on new and emerging trends is a complex issue. It is perhaps too 
early to consider methamphetamine as a new growing trend. Changes in drug use patterns can 
occur quickly (Griffiths et al., 2008) and — although the current monitoring settings at the 
EMCDDA and Europol are in place — their detection may incur some delay using the standard 
monitoring instruments such as treatment monitoring and surveys. Close links to people in contact 
with risk groups and drug users, combined with faster analysis of collected information will help to 
keep track of such changes. In this respect, the EMCDDA and Europol are committed to ongoing 
collaboration to ensure that Europe remains vigilant to any changes in the availability and use of 
methamphetamine.
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